WuXi Biologics (Cayman) Croissance future

Future contrôle des critères 3/6

WuXi Biologics (Cayman) devrait augmenter ses bénéfices et son chiffre d'affaires de 13.7% et de 10.5% par an respectivement. Le BPA devrait croître de de 13% par an. Le rendement des capitaux propres devrait être 10.3% dans 3 ans.

Informations clés

18.5%

Taux de croissance des bénéfices

17.1%

Taux de croissance du BPA

Life Sciences croissance des bénéfices	49.5%
Taux de croissance des recettes	10.8%
Rendement futur des capitaux propres	9.0%
Couverture par les analystes	Good
Dernière mise à jour	14 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

SZSC:2269 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	23,008	4,782	2,269	7,200	27
12/31/2025	20,228	4,011	1,065	6,204	29
12/31/2024	17,895	3,305	817	6,004	28
6/30/2024	17,116	2,632	-322	3,220	N/A
3/31/2024	17,075	3,016	145	3,944	N/A
12/31/2023	17,034	3,400	612	4,668	N/A
9/30/2023	16,794	3,776	N/A	N/A	N/A
6/30/2023	16,554	4,152	1,269	6,834	N/A
3/31/2023	15,911	4,286	471	6,188	N/A
12/31/2022	15,269	4,420	-327	5,542	N/A
9/30/2022	14,179	4,251	N/A	N/A	N/A
6/30/2022	13,090	4,081	-1,028	4,091	N/A
3/31/2022	11,690	3,735	-2,052	3,761	N/A
12/31/2021	10,290	3,388	-3,077	3,431	N/A
9/30/2021	9,183	3,092	-4,006	2,840	N/A
6/30/2021	8,075	2,795	-4,936	2,249	N/A
3/31/2021	6,844	2,242	-4,540	2,065	N/A
12/31/2020	5,612	1,689	-4,144	1,881	N/A
9/30/2020	4,967	1,494	-4,049	1,649	N/A
6/30/2020	4,321	1,300	-3,954	1,417	N/A
3/31/2020	4,152	1,157	-2,979	1,312	N/A
12/31/2019	3,984	1,014	-2,004	1,208	N/A
9/30/2019	3,535	922	-1,356	1,035	N/A
6/30/2019	3,087	831	-708	861	N/A
3/31/2019	2,811	731	-810	811	N/A
12/31/2018	2,534	631	-912	762	N/A
9/30/2018	2,277	520	-1,004	508	N/A
6/30/2018	2,019	410	-1,096	255	N/A
3/31/2018	1,819	331	N/A	308	N/A
12/31/2017	1,619	253	N/A	360	N/A
9/30/2017	1,429	177	N/A	320	N/A
6/30/2017	1,233	149	N/A	369	N/A
3/31/2017	1,111	145	N/A	226	N/A
12/31/2016	989	141	N/A	82	N/A
9/30/2016	889	171	N/A	162	N/A
12/31/2015	557	45	N/A	107	N/A
12/31/2014	332	42	N/A	22	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 2269 ( 13.7% par an) est supérieure au taux d'épargne ( 2.3% ).

Bénéfices vs marché: Les bénéfices de 2269 ( 13.7% par an) devraient croître plus rapidement que le marché Hong Kong ( 11% par an).

Croissance élevée des bénéfices: Les bénéfices de 2269 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 2269 ( 10.5% par an) devrait croître plus rapidement que le marché Hong Kong ( 7.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 2269 ( 10.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 2269 devrait être faible dans 3 ans ( 10.3 %).

WuXi Biologics (Cayman) Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Recent updates

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week